Teva to Report Second Quarter 2018 Financial Results on August 2, 2018

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that it
will release its second quarter 2018 financial results on Thursday,
August 2, 2018 at 7:00 a.m. ET.

Teva will host a conference call and live webcast on the same day, at
8:00 a.m. ET to discuss its second quarter 2018 results and overall
business environment. A Question & Answer session will follow this
discussion.

In order to participate, please dial the following numbers (at least 10
minutes before the scheduled start time):

For a list of other international toll-free numbers, click here.

Passcode: 6984104

A live webcast of the call will also be available on Teva’s website at: ir.tevapharm.com
Please log in at least 10 minutes prior to the conference call in order
to download the applicable software.

Following the conclusion of the call, a replay of the webcast will be
available within 24 hours on the Company’s website. The replay can also
be accessed until August 30, 2018, 9:00 a.m. ET by calling United States
1 (866) 331-1332 or International +44 (0) 3333009785; passcode: 6984104.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by millions of patients every
day. Headquartered in Israel, Teva is the world’s largest generic
medicines producer, leveraging its portfolio of more than 1,800
molecules to produce a wide range of generic products in nearly every
therapeutic area. In specialty medicines, Teva has a world-leading
position in innovative treatments for disorders of the central nervous
system, including pain, as well as a strong portfolio of respiratory
products. Teva integrates its generics and specialty capabilities in its
global research and development division to create new ways of
addressing unmet patient needs by combining drug development
capabilities with devices, services and technologies. Teva’s net
revenues in 2017 were $22.4 billion. For more information, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
regarding Teva’s generic version of Uceris®,
which are based on management’s current beliefs and expectations and are
subject to substantial risks and uncertainties, both known and unknown,
that could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to:

and other factors discussed in our Annual Report on Form 10-K for the
year ended December 31, 2017, including in the section captioned “Risk
Factors,” and in our other filings with the U.S. Securities and Exchange
Commission, which are available at www.sec.gov
and www.tevapharm.com.
Forward-looking statements speak only as of the date on which they are
made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise. You
are cautioned not to put undue reliance on these forward-looking
statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180711005286/en/

Leave a Comment